Tenaya Therapeutics, Inc. (TNYA)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
0.41 USD
0.00
(-0.613%) ⇩
(Oct. 16, 2026, 9:36 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:47 a.m. EDT
Tenaya Therapeutics presents a classic distressed biotech profile where the market has priced in a severe lack of profitability and cash burn. Fundamentally, the company is burning through cash with negative operating margins and no revenue, supported by a massive short interest of nearly 13%. While analysts offer optimistic targets based on potential clinical catalysts, the current reality is a stock trading near its 52-week lows with a cumulative loss of nearly 90% over the last four years. The recent price action confirms this bearish sentiment, with the stock drifting lower over the past two weeks despite some minor recovery attempts. Options flow reinforces this view, with traders buying deep out-of-the-money puts to hedge against further drops rather than betting on a bounce. There is no dividend to provide income, and the balance sheet, while currently liquid, faces an existential threat from its burn rate. This is a high-risk speculative vehicle suitable only for investors willing to accept total loss potential in exchange for a lottery-ticket chance at a clinical success story. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099554 |
| AutoETS | 0.099725 |
| AutoARIMA | 0.099727 |
| MSTL | 0.109447 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 18.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.109 |
| Excess Kurtosis | 0.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.689 |
| Revenue per Share | 0.007 |
| Market Cap | 91,014,960 |
| Forward P/E | -1.04 |
| Beta | 2.88 |
| Website | https://www.tenayatherapeutics.com |
As of Oct. 10, 2026, 6:47 a.m. EDT: Speculators are positioning aggressively for downside protection, evidenced by significant put volume and open interest at strikes well above the current price ($1.00 and $1.50), while call activity remains sparse and concentrated near the money. Implied volatility is elevated on out-of-the-money puts relative to calls, suggesting a market consensus of potential further decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7745856 |
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 500 |
| All Time High | 32.0 |
| All Time Low | 0.36 |
| Ask | 0.4745 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 4,917,500 |
| Average Daily Volume3 Month | 2,580,851 |
| Average Volume | 2,580,851 |
| Average Volume10Days | 4,917,500 |
| Beta | 2.877 |
| Bid | 0.2919 |
| Bid Size | 2 |
| Book Value | 0.31 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4059 |
| Current Ratio | 4.522 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.417 |
| Day Low | 0.4021 |
| Debt To Equity | 5.689 |
| Display Name | Tenaya Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -75,524,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.231 |
| Enterprise To Revenue | 13.063 |
| Enterprise Value | 17,439,536 |
| Eps Current Year | -0.41667 |
| Eps Forward | -0.392 |
| Eps Trailing Twelve Months | -0.52 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.64754 |
| Fifty Day Average Change | -0.24163997 |
| Fifty Day Average Change Percent | -0.3731661 |
| Fifty Two Week Change Percent | -77.45856 |
| Fifty Two Week High | 2.02 |
| Fifty Two Week High Change | -1.6141 |
| Fifty Two Week High Change Percent | -0.7990594 |
| Fifty Two Week Low | 0.36 |
| Fifty Two Week Low Change | 0.045899987 |
| Fifty Two Week Low Change Percent | 0.12749995 |
| Fifty Two Week Range | 0.36 - 2.02 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 211,720,220 |
| Forward Eps | -0.392 |
| Forward P E | -1.0354592 |
| Free Cashflow | -32,600,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 70 |
| Fullday Change | -0.0024999976 |
| Fullday Change Percent | -0.61334586 |
| Fullday Price | 0.4059 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,335,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00483 |
| Held Percent Institutions | 0.48886 |
| Implied Shares Outstanding | 224,230,012 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
| Long Name | Tenaya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 91,014,960 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_409125654 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -103,115,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 148,283,306 |
| Number Of Analyst Opinions | 5 |
| Open | 0.41 |
| Operating Cashflow | -52,325,000 |
| Operating Margins | -18.82793 |
| Phone | 650 825 6990 |
| Previous Close | 0.4084 |
| Price Eps Current Year | -0.9741522 |
| Price Hint | 4 |
| Price To Book | 1.3093548 |
| Price To Sales Trailing12 Months | 68.176 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.125 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0024999976 |
| Regular Market Change Percent | -0.61334586 |
| Regular Market Day High | 0.417 |
| Regular Market Day Low | 0.4021 |
| Regular Market Day Range | 0.4021 - 0.417 |
| Regular Market Open | 0.41 |
| Regular Market Previous Close | 0.4084 |
| Regular Market Price | 0.4059 |
| Regular Market Time | 1,792,157,763 |
| Regular Market Volume | 505,438 |
| Return On Assets | -0.47912997 |
| Return On Equity | -1.21859 |
| Revenue Per Share | 0.007 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 224,230,012 |
| Shares Percent Shares Out | 0.1022 |
| Shares Short | 22,922,426 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 20,774,743 |
| Short Name | Tenaya Therapeutics, Inc. |
| Short Percent Of Float | 0.1317 |
| Short Ratio | 9.61 |
| Source Interval | 15 |
| State | CA |
| Symbol | TNYA |
| Target High Price | 5.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 3.2 |
| Target Median Price | 3.0 |
| Total Cash | 78,085,000 |
| Total Cash Per Share | 0.348 |
| Total Debt | 3,949,000 |
| Total Revenue | 1,335,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.72995 |
| Two Hundred Day Average Change | -0.32405 |
| Two Hundred Day Average Change Percent | -0.44393453 |
| Type Disp | Equity |
| Volume | 505,438 |
| Website | https://www.tenayatherapeutics.com |
| Zip | 94,080 |